Business context and reporting period
Filing identity discrepancy: The request metadata identifies Lite Strategy, Inc. and 2018 Q2, but the supplied filing is MEI Pharma, Inc.’s Form 10-Q for the quarter ended December 31, 2019 (fiscal Q2 2020), with comparative periods ended December 31, 2018. The summary below reflects the filing provided.
MEI Pharma is a clinical-stage oncology company. Its four candidates are ME-401, voruciclib, ME-344 and pracinostat. The filing describes ME-401 in Phase 2 and Phase 1b studies, pracinostat in a partner-run Phase 3 trial and a Phase 2 study, and voruciclib in Phase 1b development.
Financial results and liquidity
Dollar amounts are in millions except per-share data. The company reported no product sales; revenue came from license agreements with Kyowa Kirin (KKC) and Helsinn.
| Metric | Three months ended Dec. 31, 2019 | Three months ended Dec. 31, 2018 | Six months ended Dec. 31, 2019 | Six months ended Dec. 31, 2018 |
|---|---|---|---|---|
| Revenue | $1.008 | $2.048 | $2.165 | $2.536 |
| Cost of revenue | $0.641 | $1.009 | $1.329 | $1.998 |
| Research and development | $8.281 | $9.066 | $17.243 | $15.197 |
| General and administrative | $4.195 | $3.821 | $8.325 | $7.222 |
| Loss from operations | $(12.109) | $(11.848) | $(24.732) | $(21.881) |
| Net income (loss) | $(20.217) | $12.025 | $(23.211) | $(2.517) |
| Basic loss per share | $(0.26) | $0.17 | $(0.30) | $(0.04) |
Gross profit (revenue less cost of revenue) was $0.367 million for the quarter and $0.836 million for the six-month period; corresponding gross margins were approximately 36% and 39%. No conventional operating margin is meaningful given the company’s substantial development spending and low license revenue.
- At December 31, 2019, cash and cash equivalents were $8.638 million and short-term U.S. government investments were $95.243 million, totaling $103.881 million. Total current assets were $106.445 million versus current liabilities of $9.929 million.
- Total liabilities were $29.820 million, including a $16.783 million warrant liability and deferred revenue. The balance sheet does not list borrowings or debt.
- Six-month operating cash use was $24.559 million, compared with $10.017 million in the prior-year period. Investing activities used $30.349 million, mainly because purchases of short-term investments exceeded maturities. Financing provided $53.956 million, principally from the December stock offering.
- Accumulated deficit was $254.429 million. Management said available cash and investments were expected to fund obligations and operations for at least 12 months from issuance of the financial statements.
Material changes versus the prior comparable period
- Quarterly revenue declined 51%, largely because the prior-year quarter included $0.879 million from the point-in-time transfer of the KKC license. Six-month revenue declined 15%, with lower Helsinn revenue partly offset by higher KKC revenue.
- Six-month operating loss widened to $24.732 million from $21.881 million. R&D increased $2.046 million, driven mainly by ME-401 trial costs and higher unallocated personnel and other costs; G&A increased $1.103 million. Quarterly R&D was lower year over year, chiefly due to reduced ME-401 manufacturing costs.
- The quarterly net result swung from $12.025 million of income to a $20.217 million loss. A non-cash $8.439 million warrant revaluation expense replaced a $23.437 million gain in the prior-year quarter. For the six months, the warrant revaluation gain was $0.830 million versus $18.475 million previously, contributing to the larger net loss.
- The December 2019 registered offering raised $48.5 million net by issuing 32.344 million shares at $1.60 per share. Shares outstanding rose from 73.545 million at June 30 to 105.999 million at December 31.
Outlook, management commentary, risks and unusual items
- Management expects operating losses and negative operating cash flows for the foreseeable future, and expects R&D spending to increase. The company may seek further funding through equity, debt, licensing or partnerships; there is no assurance financing will be available on acceptable terms.
- ME-401’s TIDAL Phase 2 study was amended in December 2019 to enroll only the intermittent-dosing arm, based on preliminary Phase 1b evidence of comparable activity and better tolerability. Enrollment was estimated to finish in summer 2020; the filing does not provide financial guidance.
- In reported Phase 1b interim data, the overall response rate was 81% among 73 evaluable patients with follicular lymphoma or CLL/SLL. The filing reports grade 3 diarrhea/colitis in 5% of the intermittent-schedule group versus 23% of the continuous-schedule group. These are interim clinical findings, not confirmatory trial outcomes.
- The December 2019 San Diego office lease begins June 2020 and runs through January 2028, with total contractual payments of approximately $11.5 million, plus a share of building expenses.
- Potential milestone and royalty obligations include up to $179 million under the Presage agreement and up to $74.5 million under the S*Bio agreement; none were accrued at December 31 because the relevant events had not occurred. KKC’s agreement includes up to $87.5 million in additional milestones and royalties.
- The warrant liability is Level 3 and valued using significant unobservable assumptions. Its fair-value changes can materially affect reported earnings without corresponding operating cash flows. The 16.062 million warrants outstanding are exercisable at $2.54 per share and expire in May 2023.
- Management identified clinical-trial outcomes, financing access, regulatory approval, dependence on collaborators and third parties, intellectual-property matters, and commercialization as significant risks. The company reported no legal proceedings and no material change to risk factors from its 2019 Form 10-K. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm that the intended company and reporting period are MEI Pharma and fiscal Q2 2020, rather than the metadata’s Lite Strategy and 2018 Q2.
- Review subsequent TIDAL enrollment, efficacy, safety and regulatory plans, including whether the summer 2020 enrollment estimate was achieved.
- Assess cash runway against ongoing trial spending, expected R&D increases, and the company’s stated need for potential additional financing.
- Check dilution and potential share supply from the offering, outstanding options and warrants, and remaining shelf-registration capacity.
- Track the warrant liability’s valuation sensitivity and the timing and conditions of contingent license and acquisition-related payments.
- Confirm the financial and operational implications of the new office lease and future deferred-revenue recognition.